Trial Profile
A Phase 2, Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary) ; Antineoplastics; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-890
- Sponsors OncoSec Medical
- 30 May 2023 Planned End Date changed from 1 Aug 2024 to 1 Sep 2024.
- 30 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2024.
- 30 May 2023 Status changed from recruiting to active, no longer recruiting.